ALNY
Alnylam Pharmaceuticals, Inc.
Price Chart
Latest Quote
$339.11
Current Price| Previous Close | $338.06 |
| Open | $337.42 |
| Day High | $342.24 |
| Day Low | $333.01 |
| Volume | 1,888,415 |
Stock Information
| Shares Outstanding | 132.11M |
| Total Debt | $2.77B |
| Cash Equivalents | $2.72B |
| Revenue | $3.21B |
| Net Income | $43.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $44.80B |
| P/E Ratio | 1093.90 |
| EPS (TTM) | $0.31 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 12/42| Debt to Equity | 19.32 |
| Debt to Earnings | 0.67 |
| Current Ratio | 2.78 |
| Quick Ratio | 2.61 |
| Avg Revenue Growth | 41.57% |
| Profit Margin | -12.37% |
| Return on Equity | -414.62% |
| Avg FCF Growth | -23.52% |
| FCF Yield | -0.10% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $339.11 | 1,911,100 |
| 2026-01-30 | $338.06 | 1,648,500 |
| 2026-01-29 | $346.79 | 1,681,900 |
| 2026-01-28 | $349.58 | 1,099,000 |
| 2026-01-27 | $354.75 | 988,100 |
| 2026-01-26 | $361.35 | 936,400 |
| 2026-01-23 | $357.98 | 1,636,800 |
| 2026-01-22 | $370.00 | 1,875,400 |
| 2026-01-21 | $365.46 | 1,523,500 |
| 2026-01-20 | $355.53 | 1,722,600 |
| 2026-01-16 | $359.27 | 1,527,400 |
| 2026-01-15 | $359.26 | 911,200 |
| 2026-01-14 | $366.86 | 1,250,000 |
| 2026-01-13 | $369.96 | 1,625,700 |
| 2026-01-12 | $370.91 | 3,808,000 |
| 2026-01-09 | $398.29 | 1,440,200 |
| 2026-01-08 | $399.40 | 1,400,700 |
| 2026-01-07 | $422.50 | 1,426,100 |
| 2026-01-06 | $406.40 | 1,612,900 |
| 2026-01-05 | $397.83 | 1,093,900 |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
📰 Latest News
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth
Insider Monkey • 2026-01-31T14:35:56Z
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness
Simply Wall St. • 2026-01-31T09:15:57Z
Phillip Allen Sharp Improved Human Health With Breakthroughs
Investor's Business Daily • 2026-01-29T21:09:23Z
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy
Insider Monkey • 2026-01-29T19:27:54Z
Should You Buy Alnylam Pharmaceuticals Before Feb. 12?
Motley Fool • 2026-01-28T10:04:00Z
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression
Insider Monkey • 2026-01-27T13:38:42Z
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback?
Simply Wall St. • 2026-01-14T14:07:43Z
JPM26: 2025 a “breakout year” for rare disease biotechs
Clinical Trials Arena • 2026-01-14T13:02:57Z
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
Simply Wall St. • 2026-01-14T06:11:28Z
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
Simply Wall St. • 2026-01-13T23:30:04Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $323,370,000 | $310,406,000 | $168,817,000 | $140,144,000 |
| Cost Of Revenue | $323,370,000 | $310,406,000 | $168,817,000 | $140,144,000 |
| Total Revenue | $2,248,243,000 | $1,828,292,000 | $1,037,418,000 | $844,287,000 |
| Operating Revenue | $2,248,243,000 | $1,828,292,000 | $1,037,418,000 | $844,287,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $141,858,000 | $121,221,000 | $155,968,000 | $143,021,000 |
| Total Expenses | $2,425,128,000 | $2,110,467,000 | $1,822,490,000 | $1,552,939,000 |
| Rent Expense Supplemental | $169,909,000 | $145,687,000 | $131,967,000 | $97,259,000 |
| Other Income Expense | $-180,624,000 | $-125,682,000 | $-210,761,000 | $-2,050,000 |
| Other Non Operating Income Expenses | $-6,832,000 | $-17,741,000 | $-6,204,000 | $-19,312,000 |
| Net Non Operating Interest Income Expense | $-19,866,000 | $-25,660,000 | $-131,160,000 | $-141,442,000 |
| Interest Expense Non Operating | $141,858,000 | $121,221,000 | $155,968,000 | $143,021,000 |
| Operating Expense | $2,101,758,000 | $1,800,061,000 | $1,653,673,000 | $1,412,795,000 |
| General And Administrative Expense | $975,526,000 | $795,646,000 | $770,658,000 | $620,639,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Net Interest Income | $-19,866,000 | $-25,660,000 | $-131,160,000 | $-141,442,000 |
| Interest Income | $121,992,000 | $95,561,000 | $24,808,000 | $1,579,000 |
| Normalized Income | $-150,072,296 | $-354,968,610 | $-969,555,970 | $-865,425,260 |
| Net Income From Continuing And Discontinued Operation | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Total Operating Income As Reported | $-176,885,000 | $-282,175,000 | $-785,072,000 | $-708,652,000 |
| Net Income Common Stockholders | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Net Income | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Net Income Including Noncontrolling Interests | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Net Income Continuous Operations | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Pretax Income | $-377,375,000 | $-433,517,000 | $-1,126,993,000 | $-852,144,000 |
| Special Income Charges | $0 | $0 | $-76,586,000 | $0 |
| Interest Income Non Operating | $121,992,000 | $95,561,000 | $24,808,000 | $1,579,000 |
| Operating Income | $-176,885,000 | $-282,175,000 | $-785,072,000 | $-708,652,000 |
| Gross Profit | $1,924,873,000 | $1,517,886,000 | $868,601,000 | $704,143,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Basic EPS | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-45,707,296 | $-22,667,610 | $-42,956,970 | $4,660,740 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,055,000 | $-150,301,000 | $-722,000,000 | $-636,691,000 |
| Total Unusual Items | $-173,792,000 | $-107,941,000 | $-204,557,000 | $17,262,000 |
| Total Unusual Items Excluding Goodwill | $-173,792,000 | $-107,941,000 | $-204,557,000 | $17,262,000 |
| Reconciled Depreciation | $56,670,000 | $54,054,000 | $44,468,000 | $89,694,000 |
| EBITDA (Bullshit earnings) | $-178,847,000 | $-258,242,000 | $-926,557,000 | $-619,429,000 |
| EBIT | $-235,517,000 | $-312,296,000 | $-971,025,000 | $-709,123,000 |
| Diluted Average Shares | $127,651,000 | $124,906,000 | $121,689,000 | $118,451,000 |
| Basic Average Shares | $127,651,000 | $124,906,000 | $121,689,000 | $118,451,000 |
| Diluted NI Availto Com Stockholders | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Tax Provision | $-99,218,000 | $6,725,000 | $4,163,000 | $680,000 |
| Gain On Sale Of Security | $-173,792,000 | $-107,941,000 | $-127,971,000 | $17,262,000 |
| Research And Development | $1,126,232,000 | $1,004,415,000 | $883,015,000 | $792,156,000 |
| Selling General And Administration | $975,526,000 | $795,646,000 | $770,658,000 | $620,639,000 |
| Other Gand A | $274,539,000 | $226,664,000 | $226,941,000 | $201,841,000 |
| Rent And Landing Fees | $169,909,000 | $145,687,000 | $131,967,000 | $97,259,000 |
| Salaries And Wages | $531,078,000 | $423,295,000 | $411,750,000 | $321,539,000 |
| Other Special Charges | - | - | $76,586,000 | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $67,088,000 | $-220,644,000 | $-158,223,000 | $588,203,000 |
| Total Assets | $4,239,983,000 | $3,829,880,000 | $3,546,359,000 | $3,643,304,000 |
| Total Non Current Assets | $944,698,000 | $847,183,000 | $854,112,000 | $834,728,000 |
| Other Non Current Assets | $133,903,000 | $111,293,000 | $115,482,000 | $101,095,000 |
| Non Current Deferred Assets | $116,863,000 | $10,101,000 | - | - |
| Non Current Deferred Taxes Assets | $116,863,000 | $10,101,000 | - | - |
| Current Assets | $3,295,285,000 | $2,982,697,000 | $2,692,247,000 | $2,808,576,000 |
| Other Current Assets | $116,964,000 | $126,382,000 | $132,916,000 | $88,078,000 |
| Inventory | $78,509,000 | $89,146,000 | $128,962,000 | $86,363,000 |
| Receivables | $405,308,000 | $327,787,000 | $237,963,000 | $198,571,000 |
| Accounts Receivable | $405,308,000 | $327,787,000 | $237,963,000 | $198,571,000 |
| Cash Cash Equivalents And Short Term Investments | $2,694,504,000 | $2,439,382,000 | $2,192,406,000 | $2,435,564,000 |
| Cash And Cash Equivalents | $966,428,000 | $812,688,000 | $866,394,000 | $819,975,000 |
| Prepaid Assets | - | - | - | $88,078,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $58,193,000 | $208,088,000 | $150,548,000 | - |
| Total Debt | $1,296,048,000 | $1,305,387,000 | $1,320,248,000 | $997,592,000 |
| Long Term Debt And Capital Lease Obligation | $1,254,162,000 | $1,263,877,000 | $1,278,281,000 | $957,044,000 |
| Long Term Debt | $1,024,621,000 | $1,020,776,000 | $1,016,942,000 | $675,697,000 |
| Current Debt And Capital Lease Obligation | $41,886,000 | $41,510,000 | $41,967,000 | $40,548,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $4,172,895,000 | $4,050,524,000 | $3,704,582,000 | $3,055,101,000 |
| Total Non Current Liabilities Net Minority Interest | $2,986,623,000 | $3,082,738,000 | $2,936,667,000 | $2,359,391,000 |
| Other Non Current Liabilities | $1,732,461,000 | $1,630,686,000 | $1,464,595,000 | $1,249,987,000 |
| Non Current Deferred Liabilities | $0 | $188,175,000 | $193,791,000 | $152,360,000 |
| Current Liabilities | $1,186,272,000 | $967,786,000 | $767,915,000 | $695,710,000 |
| Other Current Liabilities | $113,018,000 | $54,991,000 | $40,289,000 | $37,079,000 |
| Current Deferred Liabilities | $55,481,000 | $102,753,000 | $42,105,000 | $149,483,000 |
| Payables And Accrued Expenses | $761,488,000 | $646,362,000 | $512,864,000 | $375,017,000 |
| Payables | $88,415,000 | $55,519,000 | $98,094,000 | $73,426,000 |
| Accounts Payable | $88,415,000 | $55,519,000 | $98,094,000 | $73,426,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $67,088,000 | $-220,644,000 | $-158,223,000 | $588,203,000 |
| Total Equity Gross Minority Interest | $67,088,000 | $-220,644,000 | $-158,223,000 | $588,203,000 |
| Stockholders Equity | $67,088,000 | $-220,644,000 | $-158,223,000 | $588,203,000 |
| Gains Losses Not Affecting Retained Earnings | $-34,518,000 | $-23,375,000 | $-44,654,000 | $-33,259,000 |
| Other Equity Adjustments | $-34,518,000 | $-23,375,000 | $-44,654,000 | $-33,259,000 |
| Retained Earnings | $-7,287,748,000 | $-7,009,591,000 | $-6,569,349,000 | $-5,438,193,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $129,294,000 | $125,794,000 | $123,925,000 | $120,182,000 |
| Share Issued | $129,294,000 | $125,794,000 | $123,925,000 | $120,182,000 |
| Tangible Book Value | $67,088,000 | $-220,644,000 | $-158,223,000 | $588,203,000 |
| Invested Capital | $1,091,709,000 | $800,132,000 | $858,719,000 | $1,263,900,000 |
| Working Capital | $2,109,013,000 | $2,014,911,000 | $1,924,332,000 | $2,112,866,000 |
| Capital Lease Obligations | $271,427,000 | $284,611,000 | $303,306,000 | $321,895,000 |
| Total Capitalization | $1,091,709,000 | $800,132,000 | $858,719,000 | $1,263,900,000 |
| Additional Paid In Capital | $7,388,061,000 | $6,811,063,000 | $6,454,540,000 | $6,058,453,000 |
| Capital Stock | $1,293,000 | $1,259,000 | $1,240,000 | $1,202,000 |
| Common Stock | $1,293,000 | $1,259,000 | $1,240,000 | $1,202,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $188,175,000 | $193,791,000 | $152,360,000 |
| Long Term Capital Lease Obligation | $229,541,000 | $243,101,000 | $261,339,000 | $281,347,000 |
| Current Deferred Revenue | $55,481,000 | $102,753,000 | $42,105,000 | $149,483,000 |
| Current Capital Lease Obligation | $41,886,000 | $41,510,000 | $41,967,000 | $40,548,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $214,399,000 | $122,170,000 | $130,690,000 | $93,583,000 |
| Current Accrued Expenses | $673,073,000 | $590,843,000 | $414,770,000 | $301,591,000 |
| Net PPE | $693,932,000 | $725,789,000 | $738,630,000 | $733,633,000 |
| Accumulated Depreciation | $-270,364,000 | $-223,076,000 | $-173,450,000 | $-140,415,000 |
| Gross PPE | $964,296,000 | $948,865,000 | $912,080,000 | $874,048,000 |
| Leases | $236,686,000 | $235,411,000 | $230,848,000 | $152,045,000 |
| Construction In Progress | $7,674,000 | $30,099,000 | $14,595,000 | $80,753,000 |
| Other Properties | $362,167,000 | $354,855,000 | $343,033,000 | $336,765,000 |
| Machinery Furniture Equipment | $54,181,000 | $47,769,000 | $45,202,000 | $32,768,000 |
| Buildings And Improvements | $294,508,000 | $271,651,000 | $269,322,000 | $262,637,000 |
| Land And Improvements | $9,080,000 | $9,080,000 | $9,080,000 | $9,080,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $1,728,076,000 | $1,626,694,000 | $1,326,012,000 | $1,615,589,000 |
| Treasury Shares Number | - | $0 | - | - |
| Inventories Adjustments Allowances | - | - | $-32,700,000 | $-36,300,000 |
| Other Inventories | - | - | $-42,000 | $-38,000 |
| Finished Goods | - | - | $25,606,000 | $7,005,000 |
| Work In Process | - | - | $113,783,000 | $100,942,000 |
| Raw Materials | - | - | $22,315,000 | $14,754,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-42,589,000 | $41,945,000 | $-613,333,000 | $-718,065,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-8,312,000 | $104,156,000 | $-541,274,000 | $-641,693,000 |
| Cash Flow From Continuing Operating Activities | $-8,312,000 | $104,156,000 | $-541,274,000 | $-641,693,000 |
| Operating Gains Losses | $173,792,000 | $107,941,000 | $204,557,000 | $-17,262,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-34,277,000 | $-62,211,000 | $-72,059,000 | $-76,372,000 |
| Investing Cash Flow | $-116,840,000 | $-336,350,000 | $169,354,000 | $-273,300,000 |
| Cash Flow From Continuing Investing Activities | $-116,840,000 | $-336,350,000 | $169,354,000 | $-273,300,000 |
| Net Other Investing Changes | $-19,317,000 | $-4,438,000 | $-13,194,000 | $-4,364,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $294,159,000 | $172,131,000 | $425,753,000 | $1,247,118,000 |
| Cash Flow From Continuing Financing Activities | $294,159,000 | $172,131,000 | $425,753,000 | $1,247,118,000 |
| Net Other Financing Charges | $-8,792,000 | $24,667,000 | $-87,611,000 | $500,850,000 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Net Common Stock Issuance | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $0 | $0 | $-762,107,000 | $0 |
| Issuance Of Debt | $0 | $0 | $1,016,111,000 | $500,000,000 |
| Interest Paid Supplemental Data | $67,578,000 | $32,118,000 | $45,235,000 | $24,657,000 |
| Income Tax Paid Supplemental Data | $14,360,000 | $6,021,000 | $2,654,000 | - |
| End Cash Position | $968,652,000 | $814,884,000 | $868,556,000 | $822,153,000 |
| Beginning Cash Position | $814,884,000 | $868,556,000 | $822,153,000 | $499,046,000 |
| Effect Of Exchange Rate Changes | $-15,239,000 | $6,391,000 | $-7,430,000 | $-9,018,000 |
| Changes In Cash | $169,007,000 | $-60,063,000 | $53,833,000 | $332,125,000 |
| Proceeds From Stock Option Exercised | $302,951,000 | $147,464,000 | $259,360,000 | $246,268,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $254,004,000 | $500,000,000 |
| Net Long Term Debt Issuance | $0 | $0 | $254,004,000 | $500,000,000 |
| Long Term Debt Payments | $0 | $0 | $-762,107,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $1,016,111,000 | $500,000,000 |
| Net Investment Purchase And Sale | $-63,246,000 | $-269,701,000 | $254,607,000 | $-192,564,000 |
| Sale Of Investment | $1,571,665,000 | $1,553,800,000 | $2,231,568,000 | $1,463,550,000 |
| Purchase Of Investment | $-1,634,911,000 | $-1,823,501,000 | $-1,976,961,000 | $-1,656,114,000 |
| Net PPE Purchase And Sale | $-34,277,000 | $-62,211,000 | $-72,059,000 | $-76,372,000 |
| Purchase Of PPE | $-34,277,000 | $-62,211,000 | $-72,059,000 | $-76,372,000 |
| Change In Working Capital | $-214,084,000 | $57,261,000 | $7,618,000 | $-162,823,000 |
| Change In Other Working Capital | $-235,446,000 | $55,022,000 | $-65,911,000 | $-50,404,000 |
| Change In Payables And Accrued Expense | $91,093,000 | $80,840,000 | $191,769,000 | $88,240,000 |
| Change In Payable | $91,093,000 | $80,840,000 | $191,769,000 | $88,240,000 |
| Change In Account Payable | $91,093,000 | $80,840,000 | $191,769,000 | $88,240,000 |
| Change In Prepaid Assets | $3,229,000 | $-9,029,000 | $-38,507,000 | $-32,093,000 |
| Change In Inventory | $13,590,000 | $18,367,000 | $-34,136,000 | $-26,415,000 |
| Change In Receivables | $-86,550,000 | $-87,939,000 | $-45,597,000 | $-101,799,000 |
| Changes In Account Receivables | $-86,550,000 | $-87,939,000 | $-45,597,000 | $-101,799,000 |
| Other Non Cash Items | $88,145,000 | $104,175,000 | $104,023,000 | $135,805,000 |
| Stock Based Compensation | $272,084,000 | $221,680,000 | $230,649,000 | $165,717,000 |
| Deferred Tax | $-106,762,000 | $-713,000 | $-1,433,000 | - |
| Deferred Income Tax | $-106,762,000 | $-713,000 | $-1,433,000 | - |
| Depreciation Amortization Depletion | $56,670,000 | $54,054,000 | $44,468,000 | $89,694,000 |
| Depreciation And Amortization | $56,670,000 | $54,054,000 | $44,468,000 | $89,694,000 |
| Gain Loss On Investment Securities | $173,792,000 | $107,941,000 | $127,971,000 | $-17,262,000 |
| Net Income From Continuing Operations | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 |
| Change In Other Current Liabilities | - | $-46,502,000 | $-43,171,000 | $-40,352,000 |
| Depreciation | - | $97,031,000 | $85,550,000 | $89,694,000 |